Shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) saw an uptick in trading volume on Monday . 1,140,767 shares changed hands during trading, an increase of 92% from the previous session’s volume of 594,361 shares.The stock last traded at $0.35 and had previously closed at $0.34.

A number of research firms have recently issued reports on RTTR. Zacks Investment Research upgraded shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research note on Tuesday, September 26th. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Friday, August 4th. Finally, Chardan Capital dropped their price objective on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $2.92.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.14). sell-side analysts predict that Ritter Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

An institutional investor recently bought a new position in Ritter Pharmaceuticals stock. Susquehanna International Group LLP bought a new stake in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned about 4.49% of Ritter Pharmaceuticals as of its most recent SEC filing. 2.19% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.